Lacosamidum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 189902 |
| PubChem | 219078 |
| DrugBank | DB06218 |
| Natura chemica | |
| |
| |
| Formula summarum | C 13H 18N 2O 3 |
| Massa molaris | 250.294 g/mol |
| Natura pharmacologica | |
| Codex ATC | N03AX18 (WHO) |
| Semivita biologica | 13 horae |
| Metabolismus | iecore (hepaticus): Demethylatione CYP2C19, CYP2C9, CYP3A4 |
| Excretio | renibus |
| Ad usum therapeuticum | |
| Applicatio | per os, i.v. |
| MedlinePlus | a609028 (Anglice) |
Lacosamidum est medicamentum pharmaceuticum cum virtutibus anticonvulsivis convulsionum partialium apud adultos[1].
Historia recensere
Substantia primum anno 1996 in Houstonia ex N-benzyl-2-acetamidopropionamido derivatum descripta est[2].
Natura lacosamidi recensere
Natura chemica recensere
Nomen IUPAC suum est (2R)-N-benzylo-2-acetamido-3-methoxy-propano-amidum, massa molaris sua 250.294 g/mol. Inest praecursor chemicus benzylamidum C
6H
5CH
2NH
2, quod est benzenum cum NH2. Pariter est derivatum aminoacidorum (—NH—CO—COOH).
Natura pharmacologica recensere
Lacosamidum est medicamentum cum virtutibus anticonvulsivis. Codex ATC est N03AX18 (WHO).
Pharmacodynamica recensere
Lacosamidum canales ionticos natrii tensione reclusos (VGSC) tarde inhibit[3].
Pharmacocinetica recensere
Tempus semivitae biologicum [4] 13 horae sunt. Metabolismus per cytochromatum CYP2C19[5], CYP2C9, CYP3A4 fit. Excretio est per urinas.
Effectus lacosamidi recensere
Effectus adversarii recensere
Lacosamidum enzyma hepatica in sanguinem liberare potest, ut valores sanguinei eorum augeantur.
Usus lacosamidi recensere
Dosis diurna definita (DDD) est 300 mg per die p.o.[6]
Methodus therapeutica recensere
In morbum comitialem tractando dosis initialis sit a 50 mg ad 100 mg die, deinde hebdomade inter 50 et 100 mg die augenti, bis distributum[7], usque a 200 mg ad 400 mg die, commendatur.
Notae recensere
- ↑ Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G. D. (2007). "Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures". Epilepsia 48 (7): 1308-17
- ↑ Choi D., Stables J. P., Kohn H. (Apr 1996). "Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives". Journal of medicinal chemistry 39 (9): 1907-16
- ↑ Errington A. C., Stöhr T., Heers C., Lees G. (Ian 2008). "The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels". Molecular pharmacology 73 (1): 157-69
- ↑ Goldbook
- ↑ Cawello W., Mueller-Voessing C., Fichtner A. (Mai 2014). "Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial". Clinical drug investigation 34 (5): 317-25doi:10.1007/s40261-014-0177-2
- ↑ Systema classificationis Anatomicum Therapeuticum Chemicumque, cap. N03AX cum Pregabalini referentia,
- ↑ Benkert O, Hippius H (2017). Kompendium der Psychiatrischen Pharmakotherapie, Springer (Theodisce)
Nexus externi recensere
- LiverTox de lacosamido (Anglice)
- Lacosamidum et CYP2C19 (Anglice)